TruSight Oncology Comprehensive
Illumina, Inc. · Decision date Aug 21, 2024
What did the FDA approve?
The FDA approved Illumina's TruSight Oncology Comprehensive as a qualitative in vitro diagnostic using targeted next-generation sequencing on the Illumina NextSeq 550Dx instrument. It detects variants across 517 genes from DNA extracted from formalin-fixed, paraffin-embedded tumor tissue of patients with solid malignant neoplasms, including single nucleotide variants, multi-nucleotide variants, insertions, and deletions. RNA analysis covers fusions in 24 genes and splice variants in one gene, and the test reports a Tumor Mutational Burden score.
The approval statement describes two intended uses: as a companion diagnostic for targeted therapies listed in Table 1 of the statement, and for tumor profiling information used by qualified health care professionals according to oncology guidelines. Genomic findings beyond Table 1 are not conclusive or prescriptive for labeled use of any specific therapeutic product. The database record does not include a supplement type or reason, so no changed item or original PMA relationship is established.
FDA approval order statement
TruSight Oncology Comprehensive is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing to detect variants in 517 genes using nucleic acids extracted from formalin-fixed, paraffin embedded (FFPE) tumor tissue samples from cancer patients with solid malignant neoplasms using the Illumina NextSeq 550Dx instrument. The test can be used to detect single nucleotide variants, multi- nucleotide variants, insertions, and deletions from DNA, and fusions in 24 genes and splice variants in one gene from RNA. The test also reports a Tumor Mutational Burden (TMB) score.The test is intended to be used as a companion diagnostic to identify cancer patients who may benefit from treatment with the targeted therapies listed in Table 1, in accordance with the approved therapeutic product labeling. In addition, the test is intended to provide tumor profiling information for use by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Genomic findings other than those listed in Table 1 of the intended use statement are not conclusive or prescriptive for labeled use of any specific therapeutic product.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Pathology
- Decision date
- Aug 21, 2024
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P230011
- Regulatory pathway
- Premarket approval application
- Applicant
- Illumina, Inc.
- Product code
- PQP
- Decision code
- APPR
- Decision date
- Aug 21, 2024
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Next generation sequencing oncology panel, somatic or germline variant detection system.
- Applicant
- Illumina, Inc.
- Product code
- PQP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P230011 received
Application receipt date recorded by FDA.
P230011 · FDA decision
APPR
P230011/S008 · Related supplement
TruSight Oncology Comprehensive
Timeline entries are records held by MedtechLedger for P230011. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230011
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
TruSight Oncology ComprehensiveP230011/S008 | Illumina, Inc. | PMA supplement | Sep 4, 2026 | FDA |
Explore the linked device profile
Other records with product code PQP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Oncomine Dx Express TestP240040/S008 | Life Technologies Corporation | PMA supplement | Nov 4, 2026 | FDA |
xT CDxP210011/S006 | Tempus AI, Inc. | PMA supplement | Oct 23, 2026 | FDA |
MI Cancer SeekP240010/S007 | Caris Life Sciences | PMA supplement | Oct 16, 2026 | FDA |
FoundationOne Liquid CDx (F1LCDx)P190032/S032 | Foundation Medicine, Inc. | PMA supplement | Sep 18, 2026 | FDA |
Guardant360 CDxP200010/S029 | Guardant Health, Inc. | PMA supplement | Sep 18, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Illumina, Inc.
- Headquarters
- Not reported
- Brand website
- illumina.com
- FDA applicant address
- 5200 Illumina Way, San Diego, CA, 92122
Sources and methodology
- Original FDA record: P230011
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


